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Abstract
Background: Familial non-medullary thyroid cancer (FNMTC) is associated with a higher rate of
multifocality and a higher recurrence rate than sporadic thyroid cancer. However, the effect of
FNMTC on life expectancy is unknown.
Material and Methods: Using data from our FNMTC database, we calculated life expectancy and
survival rates after diagnosis of FNMTC and compared the results with the rates for unaffected
family members and for the standard US population. Overall life expectancy and survival rates
were calculated using the Kaplan–Meier method. We compared patients from families with 2
affected members with patients from families with ‡3 affected members. We also compared
patients diagnosed in a known familial setting (index cases and subsequent cases) with patients
diagnosed before the familial setting was recognized.
Results: There were 139 affected patients with 757 unaffected family members. The mean age at
diagnosis was 40.8 – 13.9 years and the mean follow-up time was 9.4 – 11.7 years. Ten patients
died of thyroid cancer during follow-up. The life expectancy of patients with FNMTC was similar to
that of their unaffected family members. Survival was significantly shorter for patients with 3 or
more affected family members, for patients diagnosed before the familial setting was recognized,
and for patients with anaplastic cancer.
Conclusions: Our results suggest that FNMTC may be more aggressive than sporadic thyroid
cancer, particularly in families with 3 or more affected members. However, when recognized and
treated appropriately, it does not significantly shorten the overall life expectancy of the affected
patients.
Most thyroid cancers of follicular cell origin (papillarythyroid carcinoma, follicular thyroid carcinoma and Hurthle cell carcinoma) are sporadic; however, familialclustering of non-medullary thyroid cancer (NMTC) has
been shown in epidemiological studies, indicating a
familial relative risk of 4.23–10.3.1–4 Because the genetic
abnormality leading to familial NMTC (FNMTC) is un-
known,5 the current definition of FNMTC is based on
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having 2 direct relatives affected by thyroid cancer who
do not have other familial syndromes such as Cowden
disease (multiple hamartoma syndrome), familial adeno-
matous polyposis (FAP), or Carney complex.6 However,
because of the high prevalence of thyroid cancer in the
general population, it has been estimated that if 2 family
members are affected with NMTC, there is a 53% chance
that this cancer is familial in origin and a 47% chance that
it is sporadic. If 3 or more family members are affected,
there is a 99.9% chance that the disease is familial.7,8
Familial NMTC accounts for 3%–7% of differentiated
thyroid cancer and is a recognized clinical entity char-
acterized by a more aggressive phenotype.7,9,10 FNMTC
occurs at a younger age, is more often multifocal, and
recurs more often than its sporadic counterpart.9–13
However, its effect on mortality is still unclear.9,14
Therefore, we analyzed the FNMTC database of pa-
tients seen either at our institution (University of Cali-
fornia, San Francisco, UCSF) and at several other
institutions in the United States. Survival and life
expectancy of FNMTC patients with 2 affected family
members or ‡3 affected members were compared with
those of unaffected family members. Survival was also
compared with the estimated survival of the standard
US population.
PATIENTS AND METHODS
We retrospectively analyzed data on cases in the
FNMTC Database at UCSF that were diagnosed between
1974 and 2004. Data on patients with FNMTC and their
family members have been collected prospectively in this
database. Cases that are defined as familial if 2 first-
degree relatives were affected by histopathologically
confirmed thyroid cancer of follicular cell origin, are
initially reported by UCSF physicians and surgeons and
by collaborating physicians and surgeons in the US. The
database variables consist of the demographics of the
patients, a pedigree with the family history, the operation,
pathology, and clinic visit reports of the affected family
members. Additional data for this study was extracted
from patients medical records and updated either by di-
rect patient contact (follow-up visit or telephone call) or by
sending questionnaires to the patient, the reporting phy-
sician or surgeon, or both. Patients with occult thyroid
cancer discovered by pathologic examination after thy-
roidectomy for a benign condition were considered to be
affected with FNMTC because previous studies have
suggested that even microcarcinomas have a more se-
vere prognosis in a familial setting.12 Family members
were considered non-affected when they had a benign
thyroid disease or no known thyroid disease and were
considered affected when they had a histopathologically
proven thyroid cancer.
Patients were separated into 2 initial groups for analy-
sis: one group consisted of patients from families with 2
members affected by FNMTC (Group 2); the other con-
sisted of patients from families with ‡3 affected members
(Group ‡3). Within each family, patients were also sep-
arated into 2 groups: those with FNMTC diagnosed in a
recognized familial setting (the index case and sub-
sequent cases in that family; the ‘‘Post-index’’ Group) and
those diagnosed before the index case (the ‘‘Pre-index’’
Group). In order to compare the survival of patients with
FNMTC with that of the standard US population, for each
patient with FNMTC, a control case was created with the
average number of years of life remaining derived from
the United States life tables, specific for gender, race, and
decennial period.15 The study endpoints were age and
status at the last follow-up. The study was approved by
the UCSF Committee on Human Research.
Results are presented as mean values – standard
deviation (SD) unless otherwise stated. Comparisons
between groups were made using the Chi-square test,
Fishers exact test, Students t-test or analysis of variance
(ANOVA). When overall comparisons showed a signifi-
cant difference, pairwise comparisons were carried out
using Bonferronis correction. Overall life expectancy and
survival after FNMTC diagnosis were analyzed using the
Kaplan–Meier method and groups were compared using
the log-rank test. Follow-up times were analyzed up to 25
years after FNMTC diagnosis because <10% of patients
were remaining after that time point. P values <0.05 were
considered statistically significant. Statistical analyses
were performed and graphs were generated with SPSS
software version 11.0.1 (SPSS, Chicago, IL, USA). Leg-
ends and numbers at risk were added on the graphs
using Adobe Photoshop Elements (Adobe Systems
Incorporated, San Jose, CA, USA).
RESULTS
Life Expectancy
Of the 199 patients with FNMTC in the database, 139
(69.8%) had a pedigree available with data on age and
health status for them and their 757 non-affected family
members. Characteristics of the 139 patients with
FNMTC are given in Table 1. The overall life expectancy
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of male and female FNMTC patients was not signifi-
cantly shorter than that of their same-sex non-affected
family members (Figs. 1, 2). The mean (95% confidence
interval) life expectancy was 81 (72–89) years for female
patients, 80 (77–82) years for their non-affected female
family members, 78 (70–82) years for male patients,
and 73 (70–76) for their non-affected male family
members.
Survival after FNMTC Diagnosis
The mean follow-up time after FNMTC diagnosis was
9.4 – 11.7 years. By the end of follow-up, 10 patients
had died of thyroid cancer (7.2%, 4 females and 6
males; age 60.3 – 14.2 years). Seven additional patients
(5.0%, 4 females and 3 males, age 75 – 13.6 years) had
died of other causes. Although the overall mortality rate
for FNMTC patients was significantly higher than that for
standard US controls during the first 30 years after
FNMTC diagnosis, the overall difference was not sta-
tistically significant. (Fig. 3). The mean (95% CI) overall
survival was slightly but not significantly better for wo-
men than for men [at 10 years: 91% (83–99) vs. 86%
(76–96), at 20 years: 87% (76–96) vs. 67% (42–92),
P = 0.11].
Figure 2. Kaplan–Meier curves representing life expectancy of
male patients with FNMTC and their unaffected male family
members. The number of patients and unaffected family
members remaining at each time point is shown below the
graph.
Table 1.
Characteristics of the 139 familial non-medullary thyroid cancer
(FNMTC) patients
Characteristic Statistic
Age at FNMTC diagnosis (years) 40.8 – 13.9
Sex ratio (male/female) 0.47 (45/94)
Average follow-up time (years) 9.4 – 11.7
Number belonging to families with...
2 affected members 61 (46.9%)




Hurthle cell 6 (4.5%)
Anaplastic 3 (2.3%)
Results are shown as mean – SD or values (percent).
Figure 1. Kaplan–Meier curves representing life expectancy of
female patients with familial non-medullary thyroid cancer
(FNMTC) and their unaffected female family members. The
number of patients and unaffected family members remaining at
each time point is shown below the graph.
Figure 3. Kaplan–Meier curves representing overall and dis-
ease-specific cumulative mortality of FNMTC patients according
to follow-up time after FNMTC diagnosis and of control cases
derived from standard US population life tables. The number of
patients remaining at each time point is shown below the graph.
Comparison was made between the overall mortality of the
patients and the controls.
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Prognostic Factors
Although their demographic and histology characteris-
tics were similar (Table 2), patients in Group ‡3 had a
shorter survival time than patients in Group 2 (P = 0.02).
Moreover, the survival rates of patients in Group ‡3 were
significantly lower than those of the controls (Fig. 4),
while the survival rates of patients in Group 2 were similar
to those of the controls (Fig. 5). The survival rates of
patients in the pre-index group were significantly lower
than those of the patients in the post-index group (Fig. 6).
In fact, none of the patients died in the post-index group
after a mean follow-up time of 6.5 – 9.2 years. As ex-
pected, the proportion of patients who died during follow-
up differed significantly according to tumor histology: 6
out of 114 patients with papillary thyroid cancer, 0 out of
10 with follicular thyroid cancer, 1 out of 6 with Hurthle cell
thyroid cancer, and 3 out of 3 with anaplastic thyroid
cancer. Pairwise comparison testing showed that the
proportion who died of anaplastic cancer was significantly
different from the 3 other types of tumors (P < 0.01), but
not among the 3 types of differentiated thyroid cancer.
DISCUSSION
Our retrospective study shows that after treatment,
FNMTC does not significantly affect the overall life
expectancy or survival of patients when compared with
their non-affected family members or with the standard
US population. However, among patients with FNMTC,
those from families with 3 or more affected members had
significantly shorter survival times than those from
Table 2.
Characteristics of FNMTC patients from families with 2 or ‡ 3 affected members
2 members affected (n = 61) ‡ 3 members affected (n = 69) P
Age at FNMTC diagnosis (years) 41.1 – 13.3 41.3 – 15 0.93*
Sex ratio (male/female) 0.45 (19/42) 0.53 (24/45) 0.66*
Follow-up time (years) 8.9 – 11.3 10.0 – 12.7 0.60*
Histology 0.12**
Papillary 51 (86.4%) 54 (83.1%)
Follicular 7 (11.9%) 3 (4.6%)
Hurthle cell 1 (1.7%) 5 (7.7%)
Anaplastic 0 3 (4.6%)
Results are mean – SD or values (percent).
*Students t-test, **Pearsons Chi-square test.
Figure 4. Kaplan–Meier curves representing the cumulative
survival of FNMTC patients from families with 3 or more affected
members and of control cases derived from standard US
population life tables. The number of patients remaining at each
time point is shown below the graph.
Figure 5. Kaplan–Meier curves representing the cumulative
survival of FNMTC patients from families with 2 affected
members and of control cases derived from standard US
population life tables. The number of patients remaining at each
time point is shown below the graph.
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families with only 2 affected members. Similarly, patients
who were diagnosed before the index case (the ‘‘pre-
index’’ group) had significantly shorter survival times than
those with a known family history of thyroid cancer (the
‘‘post index’’ group). Moreover, anaplastic thyroid cancer
was a significant factor of death in this study.
Our study included patients with anaplastic cancer be-
cause we considered the occurrence of anaplastic thyroid
cancer to be a probable de-differentiation of papillary
thyroid cancer. One patient with anaplastic thyroid cancer
came from a family in which 2 other members had pap-
illary thyroid cancer. The 2 other patients came from the
same family, in which 11 other members had papillary
thyroid cancer. Because these 3 patients accounted for
30% of the disease-specific deaths in our study, if we
excluded them from the analysis, the survival rates and
the life expectancy for patients with FNMTC would in-
crease.
Patients with differentiated thyroid cancer have an
excellent 10-year survival rate, ranging between 80% and
95%.16,17 This high survival rate makes statistical com-
parisons between different groups of patients or even
between patients and the normal population difficult,
particularly when the groups (and therefore the sub-
groups) are relatively small. Moreover, most of the stud-
ies on thyroid cancer, like ours, use overall mortality
(death from any cause) and not the specific mortality
(death from thyroid cancer) as their endpoints. We pre-
viously reported that about 50% of the deaths in patients
with differentiated thyroid cancer are due to the thyroid
cancer and 50% to other causes.18 Moreover, the stan-
dard survival curves express survival in years alive, irre-
spective of age.19 However, we believe age at diagnosis
should also be taken into account because, for example,
the overall 10-year expected mortality rate for a healthy
20-year-old woman is much lower than that of a healthy
70-year-old man and thyroid cancer occurs throughout all
decades of life.19 In our study, the youngest patient was
diagnosed at age 10 and the oldest was diagnosed at age
80.
To address these problems, we first used overall life
expectancy to compare groups of patients. As a result,
age at death was analyzed, irrespective of the age at
diagnosis, thereby giving an indication of the influence of
FNMTC on life expectancy. When life expectancy is used,
a patient who is diagnosed at age 20 and dies 5 years
later has a bigger influence on the resulting life expec-
tancy than a patient who is diagnosed at age 70 and dies
5 years later, whereas both patients would have the same
influence on standard survival curves that express sur-
vival in terms of years alive. We chose the non-affected
family members as controls in this life expectancy anal-
ysis because, in our opinion, they are better controls than
the standard population as a result of being ‘‘naturally’’
matched not only for age, sex and race, which are known
factors influencing life expectancy and which can be
found in standard life tables, but also for economic status,
for exposure to environmental factors like tobacco
smoke, and for genetic background. All of these factors
are known to influence life expectancy, but cannot be
adjusted for in standard life tables. We found that life
expectancy was similar for FNMTC patients and their
non-affected family members, suggesting that overall and
after treatment, FNMTC does not significantly adversely
affect the life expectancy of patients. However, life
expectancy analysis also has several limitations.
As the gene or genes involved in FNMTC are not
known, all the family members who were not diagnosed
with thyroid cancer were considered to be unaffected.
However, previous studies have shown that when sys-
tematic ultrasound is performed in family members of
FNMTC patients, 77 (52%) of the 149 patients examined
had at least one nodule and 15 (10%) of the 18 patients
undergoing thyroidectomy had thyroid cancer,20 sug-
gesting that, as in the case of sporadic NMTC, FNMTC
can be unrecognized for a long period of time. Moreover,
as only the patients with proven NMTC were included in
the affected group for our study, all the other family
members who died of other causes, perhaps before
developing FNMTC, were included in the non-affected
Figure 6. Kaplan–Meier curves representing the cumulative
survival of FNMTC patients diagnosed in a known familial
setting (post-index group) and patients diagnosed before the
familial setting was recognized (pre-index group) according to
the follow-up time after diagnosis. The number of patients at risk
at each time point is shown below the graph.
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group. We found that 19 controls (13 men and 6 women)
in the non-affected group died between the ages of 10
and 40. However, even when these controls were ex-
cluded, life expectancy did not differ between the FNMTC
patients and their non-affected relatives (P = 0.94 for the
females and 0.30 for the males).
To address the problem of standard survival curves that
express survival in years alive, irrespective of age, we
used cases that were matched to patients by age, sex,
decennial period at diagnosis, and race. By comparing
survival of FNMTC patients with that of these controls
took age at diagnosis into account because the 2 groups
have the same age distribution at diagnosis. We found
that the survival of patients from families with 2 affected
members had similar survival rates as controls, but that
patients from families with ‡3 affected members had
significantly lower survival rates than controls, suggesting
that FNMTC is more aggressive when ‡3 family members
are affected. Although worse disease-free survival has
been shown in patients from families with 3 or more af-
fected members,6,10 our finding of a worse overall sur-
vival is new and, in our opinion, reflects a more significant
impact of FNMTC. The aggressiveness of FNMTC is
controversial, including the impact on survival; however,
none of the previous studies addressed the survival of
FNMTC patients from families with ‡3 affected mem-
bers.9,21 Based on the prevalence of thyroid cancer in the
general population, Charkes hypothesis that 47% of the
families with only 2 affected members could be consid-
ered sporadic cases of NMTC8 suggests that there may
be a dilution effect in the group of patients from families
with 2 affected members. Therefore, the aggressiveness
of FNMTC could be underestimated by the presence of a
significant number of sporadic NMTC patients in this
group and our analysis of patients from families with ‡3
affected members thus provides more precise data on the
effect of FNMTC on survival than an analysis of all pa-
tients from families with 2 or more affected members.
Two additional factors were significantly associated
with death during follow-up in this study. First, all 3 pa-
tients with anaplastic cancer died of their disease, as
expected. The second factor we identified was that
compared with being diagnosed with NMTC before the
familial group is recognized, being diagnosed in a known
familial setting appears to be associated with a better
outcome. The important clinical implication of this finding
is that an accurate family history could be a more
important prognostic factor than the extent of surgery in a
significant number of patients with thyroid cancer. How-
ever, because our study was retrospective and patients
from throughout the United States were included in the
database, it was not possible to analyze whether the
physicians who cared for these patients and their rela-
tives were more aggressive about follow-up or treatment
protocols for patients with FNMTC and their relatives than
they were for patients who were not diagnosed in a
familial setting. For relatives of FNMTC patients being
followed at our institution, we recommend regular ultra-
sound examination of the thyroid and yearly follow-up or
total thyroidectomy when a nodule is found. This recom-
mendation is based on the fact that FNMTC is often
multifocal and that we have previously shown that fine-
needle aspiration cytology was not as accurate in patients
with FNMTC as in patients with sporadic NMTC.22 In that
study, 3 (12%) FNMTC patients had a false negative
cytology. However, this aggressive approach is only jus-
tified when thyroidectomy is associated with a very low
risk of hypoparathyroidism and recurrent nerve injury.7
In conclusion, this study documents that FNMTC does
not significantly affect the overall life expectancy of trea-
ted patients compared with their non-affected relatives or
with the US population. However, being from a family in
which 3 or more members are affected with thyroid can-
cer is associated with a significantly lower survival, as
does being diagnosed with NMTC before it is recognized
as a familial disease. Further studies are needed to
determine the optimal management of patients with
FNMTC; however, patients with 3 or more affected family
members possibly deserve a more aggressive surgical
and follow-up management than patients with sporadic
thyroid cancer.
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